Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 26;187(26):7585-7602.e25.
doi: 10.1016/j.cell.2024.11.006. Epub 2024 Dec 9.

Dual BACH1 regulation by complementary SCF-type E3 ligases

Affiliations

Dual BACH1 regulation by complementary SCF-type E3 ligases

Benedikt Goretzki et al. Cell. .

Abstract

Broad-complex, tramtrack, and bric-à-brac domain (BTB) and CNC homolog 1 (BACH1) is a key regulator of the cellular oxidative stress response and an oncogene that undergoes tight post-translational control by two distinct F-box ubiquitin ligases, SCFFBXO22 and SCFFBXL17. However, how both ligases recognize BACH1 under oxidative stress is unclear. In our study, we elucidate the mechanism by which FBXO22 recognizes a quaternary degron in a domain-swapped β-sheet of the BACH1 BTB dimer. Cancer-associated mutations and cysteine modifications destabilize the degron and impair FBXO22 binding but simultaneously expose an otherwise shielded degron in the dimer interface, allowing FBXL17 to recognize BACH1 as a monomer. These findings shed light on a ligase switch mechanism that enables post-translational regulation of BACH1 by complementary ligases depending on the stability of its BTB domain. Our results provide mechanistic insights into the oxidative stress response and may spur therapeutic approaches for targeting oxidative stress-related disorders and cancer.

Keywords: BACH1; Cullin-RING ligases; F-box; FBXL17; FBXO22; S-nitrosylation heme; cysteine modification; ligase switch; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests All listed authors are or were employees and/or shareholders of Novartis Pharma.

MeSH terms

Substances

LinkOut - more resources